Tan, Darren Jun Hao and Ng, Cheng Han and Muthiah, Mark and Yong, Jie Ning and Chee, Douglas and Teng, Margaret and Wong, Zhen Yu and Zeng, Rebecca Wenling and Chin, Yip Han and Wang, Jiong-Wei and Danpanichkul, Pojsakorn and Rajaram, Ruveena Bhavani and DasGupta, Ramanuj and Suzuki, Hiroyuki and Takahashi, Hirokazu and Tamaki, Nobuharu and Dan, Yock Young and Lui, Rashid and Duseja, Ajay and Siddiqui, Mohammad Shadab and Yeoh, Khay Guan and Sanyal, Arun and Wijarnpreecha, Karn and Loomba, Rohit and Mantzoros, Christos Socrates and Huang, Daniel Q. (2024) Rising global burden of cancer attributable to high BMI from 2010 to 2019. Metabolism-Clinical and Experimental, 152. p. 155744. ISSN 0026-0495, DOI https://doi.org/10.1016/j.metabol.2023.155744.
Full text not available from this repository.Abstract
Background: High body mass index (BMI) is a major risk factor for cancer development, but its impact on the global burden of cancer remains unclear. Methods: We estimated global and regional temporal trends in the burden of cancer attributable to high BMI, and the contributions of various cancer types using the framework of the Global Burden of Disease Study. Results: From 2010 to 2019, there was a 35 % increase in deaths and a 34 % increase in disability-adjusted life-years from cancers attributable to high BMI. The age-standardized death rates for cancer attributable to high BMI increased over the study period (annual percentage change APC] +0.48 %, 95 % CI 0.22 to 0.74 %). The greatest number of deaths from cancer attributable to high BMI occurred in Europe, but the fastest-growing age-standardized death rates and disability-adjusted life-years occurred in Southeast Asia. Liver cancer was the fastest-growing cause of cancer mortality (APC: 1.37 %, 95 % CI 1.25 to 1.49 %) attributable to high BMI. Conclusion: The global burden of cancer-related deaths attributable to high BMI has increased substantially from 2010 to 2019. The greatest increase in age-standardized death rates occurred in Southeast Asia, and liver cancer is the fastest-growing cause of cancer mortality attributable to high BMI. Urgent and sustained measures are required at a global and regional level to reverse these trends and slow the growing burden of cancer attributed to high BMI.
| Item Type: | Article |
|---|---|
| Funders: | United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Heart Lung & Blood Institute (NHLBI) (U01DK061734); (R01DK106419); (P30DK120515); (R01DK121378); (R01DK124318), Bristol-Myer Squibb (P01HL147835), Eli Lilly, Galmed, Metacrine, Inc., NGM Bio-pharmaceuticals, Arrowhead Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Galmed Pharmaceu-ticals, NGM Biopharmaceuticals, Novo Nordisk Novo Nordisk Foundation, National Medical Research Council, Singapore (MOH-OFLCG18May-0003), Agency for Science Technology & Research (A*STAR), Ministry of Health-Singapore National Medical Research Council, Singapore UK Research & Innovation (UKRI) Medical Research Council UK (MRC) (IAF-ICP I2101E0012), Massachusetts Life Sciences Center (MOH-000595-01), Coherus Inc., Merck & Company, Boehringer Ingelheim, Elsevier |
| Uncontrolled Keywords: | Cancer; Epidemiology; Etiology; Obesity |
| Subjects: | R Medicine > R Medicine (General) |
| Divisions: | Faculty of Medicine Universiti Malaya Medical Centre (UMMC) |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 14 Nov 2024 05:12 |
| Last Modified: | 14 Nov 2024 05:12 |
| URI: | http://eprints.um.edu.my/id/eprint/45921 |
Actions (login required)
 |
View Item |
